On January 7, 2016 OncoResponse, an immuno-oncology antibody discovery company, and the Knight Cancer Institute at Oregon Health & Science University reported a collaboration to identify antibodies against novel targets in elite responders to cancer immunotherapy (Press release, OncoResponse, JAN 7, 2016, View Source [SID1234516435]). The agreement provides OncoResponse with access to OHSU patient samples in two cancer indications, prostate cancer and chronic myeloid leukemia (CML), for immune repertoire screening to identify antibodies with exceptional reactivity from patients who have elite responses to cancer immunotherapies.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"By interrogating the humoral response of patients who have responded exceptionally well to immunotherapy, we can identify rare cancer-fighting antibodies and novel targets that may lead to the development of improved cancer treatments," said Clifford J. Stocks, CEO of OncoResponse. "This collaboration will allow us access to invaluable patient sample sets that will undoubtedly be instrumental to the understanding of the immune response to cancer."
Using a validated platform technology to rapidly screen antibodies made by the human immune system, OncoResponse scientists will identify those with exceptional reactivity and leverage this knowledge to identify potential targets for novel therapeutic development. Financial terms of the agreement were not disclosed.
"We are deeply committed to the development of improved cancer treatments for patients in need," said Tomasz Beer, M.D., deputy director, OHSU Knight Cancer Institute. "This collaboration will provide valuable data that will allow us to develop a better understanding of what makes certain treatments successful and will inform the development of new therapies that have the potential to significantly impact patients’ lives."